PASTEUR Act of 2026

This bill would let the Secretary of Health and Human Services sign contracts with makers of new antimicrobial drugs that treat drug-resistant infections. Drugs would be scored on patient benefits, innovation, and public health value, and approved contracts would pay drugmakers between $75 million and $300 million per year, reduced by U.S. sales revenue, for up to 10 years. In return, companies would have to keep the drug available, report resistance data, and follow appropriate-use and manufacturing practices. The bill would also create a 15-member advisory group, fund grants for hospital and outpatient antibiotic stewardship programs, expand federal tracking of antimicrobial use and resistance, and appropriate $6 billion.

Full text and official record on Congress.gov

Sponsors

• Michael F. Bennet Democrat sponsor
• 4 cosponsors